Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With a Checkpoint Inhibitor for Subjects With Advanced Solid Tumors

NCT05601219 is registered in ClinicalTrials.gov with Adanate, Inc as lead sponsor.

NCT NCT05601219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05601219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With a Checkpoint Inhibitor for Subjects With Advanced Solid Tumors
Lead sponsor
Adanate, Inc
Phase
Phase 1
Overall status
Terminated
Start date
November 15, 2022
Completion date
October 30, 2024
Enrollment
46 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult